Navigation Links
Anticoagulant Drugs Had Similar Outcomes After Angioplasty
Date:3/30/2008

Study also finds drug-releasing stents appear to work better than uncoated ones

SUNDAY, March 30 (HealthDay News) -- In heart attack patients who had angioplasty, the anticoagulant drugs abciximab and tirofiban produced similar outcomes for certain cardiac measures within 90 minutes after the procedure, says an Italian study.

The researchers also found that patients who received coated stents that released the drug sirolimus had a lower risk of major adverse cardiac events within eight months than patients who received uncoated stents.

The study was to be presented Sunday at the American College of Cardiology annual meeting in Chicago. It was also to be published online Sunday in the Journal of the American Medical Association and will appear in the April 16 print issue.

Treatment with abciximab and implantation of an uncoated stent is a treatment strategy used to reduce the risk of major adverse cardiac events (MACE) in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI - a certain pattern on an electrocardiogram after a heart attack), according to background information in the study.

The researchers noted it hasn't been clear whether using tirofiban instead of abciximab would provide similar benefits. They added that the use of drug-eluting stents instead of uncoated stents in this patient population is discouraged because of safety concerns and conflicting evidence about efficacy.

In this study, Dr. Marco Valgimigli, of the Cardiovascular Institute at the University of Ferrara, and his colleagues compared high-dose tirofiban and sirolimus-releasing stents with abciximab infusion and uncoated stents in 745 patients with STEMI undergoing angioplasty. They found that ST-segment elevation was reduced by at least 50 percent within 90 minutes after angioplasty in 83.6 percent of patients in the abciximab group and in 85.3 percent of those in the tirofiban group.

At eight months, the MACE rate among those treated with tirofiban was 9.9 percent, compared to 12.4 percent in the abciximab group. The MACE rate among patients who received uncoated stents was 14.5 percent, compared with 7.8 percent among those who received the drug-releasing stent. The rate of revascularization (a repeat procedure to unblock a blood vessel) was 3.2 percent among patients who received the drug-coated stent, compared with 10.2 percent among patients who received an uncoated stent.

"In summary, our study provides evidence that in a broad population of largely unselected patients undergoing PCI for STEMI, tirofiban therapy is associated with a noninferior resolution from ST-segment elevation at 90 minutes post-intervention compared with abciximab, and at eight-month follow-up, MACE are approximately halved by sirolimus-eluting stent implantation compared with uncoated stents," the study authors wrote.

More information

The U.S. National Heart, Lung, and Blood Institute has more about angioplasty.



-- Robert Preidt



SOURCES: JAMA/Archives journals, news release, March 30, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Different anticoagulant regimens yield equal results
2. Comparison of anticoagulants for angioplasty show similar outcomes
3. New review suggests caution on drugs to raise good cholesterol
4. Can cancer drugs combine forces?
5. Study provides hope that some transplant patients could live free of antirejection drugs
6. Study provides hope that some transplant patients could live free of anti-rejection drugs
7. RA Drugs Linked to Slight Skin Cancer Risk
8. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
9. Rock N Roll: Sex, Drugs and an Early Exit
10. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anticoagulant Drugs Had Similar Outcomes After Angioplasty
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... ... , ... Dr. Robert Mondavi, one of the dentists in Torrance , ... fast-growing field as more patients are discovering the many different ways they can change ... currently available to them and which ones might work for their smiles. , ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed Begley Jr., ... episode, airing third quarter 2016 via Discovery Channel. Dates and show times TBA. ... Products, located in Greenwood, Wisconsin applies product research and development and continuous technological ...
(Date:4/29/2016)... Village, CA (PRWEB) , ... April 29, 2016 ... ... Philadelphia Pet Expo to promote their animal line of probiotics, Petbiotics ™, ... see the large turnout of animal rescue groups networking for their non-profit organizations. ...
(Date:4/29/2016)... ... 2016 , ... Intellitec Solutions will be a sponsor at ... the Broward County Convention Center. The event is a chance for finance professionals ... public facility management. Intellitec Solutions will highlight their customized accounting solutions designed for ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... the development of oral drug delivery systems, announced today that ... presented by Joseph Gunnar & Co. LLC, taking ... . Nadav Kidron , CEO of Oramed, will ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/27/2016)... Mass., April 27, 2016  Hologic, Inc. (Nasdaq: ... financial results for the fiscal second quarter ended ... (EPS) of $0.24 increased 41.2%, and non-GAAP diluted ... million increased 5.8% on a reported basis, and ... "We posted another good quarter, highlighted by ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology: